What are the indications and uses of mometasone furoate 0.1% cream?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Indications and Uses of Mometasone Furoate 0.1% Cream

Mometasone furoate 0.1% cream is FDA-approved for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age and older. 1

Primary Indications

Atopic Dermatitis (Eczema)

Mometasone furoate 0.1% cream is classified as a medium-potency topical corticosteroid and serves as an effective treatment option for atopic dermatitis across multiple age groups. 2

  • Pediatric patients (1-12 months): In infants with facial atopic dermatitis, mometasone furoate 0.1% cream applied twice daily for 10 days demonstrated safety comparable to vehicle, with significant improvements in EASI scores, itch response, and quality of life 2

  • Children and adolescents: Effective for moderate-to-severe atopic dermatitis when applied twice daily 2

  • Maintenance therapy: Medium-potency topical corticosteroids like mometasone can be used up to 3 times per week for maintenance therapy in patients with frequently relapsing disease to reduce flares and increase comfort 2

Psoriasis

Mometasone furoate 0.1% cream demonstrates efficacy in psoriasis management:

  • Psoriasis vulgaris: Applied once daily for 2-8 weeks, mometasone 0.1% was generally more effective than other corticosteroids of similar or weaker potency 3

  • Combination therapy: When combined with tazarotene gel, mometasone cream showed superior efficacy compared to mometasone alone, both during therapy and for duration of therapeutic effect 4

  • The mometasone ointment formulation (0.1%) is classified as high-potency (Class II), while the cream formulation is medium-potency (Class III-IV) 2, 5

Other Corticosteroid-Responsive Dermatoses

Mometasone furoate 0.1% cream is effective for:

  • Seborrheic dermatitis: More effective than ketoconazole 2.0% and hydrocortisone 1.0% in 4-6 week trials 3

  • Allergic contact dermatitis: Demonstrated 93.6% average improvement after 21 days of once-daily application 6

  • Lichen sclerosus: Effective alternative to clobetasol propionate with similar efficacy but potentially higher safety profile 7, 8

  • Lichen simplex chronicus: Effective treatment, particularly when used under hydrocolloid dressing 9

Dosing and Application

Apply a thin film once daily to affected skin areas. 1

Key Dosing Considerations:

  • Pediatric use: Approved for children ≥2 years of age; safety and efficacy for >3 weeks use not established in pediatric patients 1

  • Not recommended: Children <2 years of age 1

  • Discontinue therapy when control is achieved; if no improvement within 2 weeks, reassess diagnosis 1

  • Avoid occlusive dressings unless directed by physician 1

  • Do not apply in diaper area if child requires diapers or plastic pants 1

Anatomical Site Considerations

Use lower potency agents on face, neck, genitals, and body folds due to increased absorption and atrophy risk in these areas. 2 The cream formulation of mometasone (medium potency) is more appropriate for these sensitive areas compared to the ointment formulation (high potency).

Safety Profile

Mometasone furoate demonstrates a favorable benefit-to-risk ratio:

  • Low HPA axis suppression potential: Approximately half as potent as betamethasone valerate in suppressing hypothalamic-pituitary-adrenal axis function 3, 10

  • Low atrophogenic potential: No greater than other corticosteroids in its class 3

  • Well-tolerated: Transient, mild-to-moderate local adverse effects (burning, stinging, folliculitis, dryness) may occur 3

  • Low sensitization risk: Preliminary patch test studies show low risk of primary sensitization and cross-reactions 3

Common Pitfalls to Avoid

  • Steroid phobia: Educate patients that when used appropriately, topical corticosteroids are safe and effective; patient concerns average 6.5/10 on distress scales 2

  • Inappropriate potency selection: Remember the cream formulation is medium-potency (Class III-IV), while the ointment is high-potency (Class II) 2

  • Overuse in young children: Limit use to ≤3 weeks in pediatric patients without established long-term safety data 1

  • Occlusion in infants: Never use under diapers or plastic pants as these create occlusive conditions 1

References

Guideline

guidelines of care for the management of atopic dermatitis in pediatric patients.

Journal of the American Academy of Dermatology, 2026

Research

Topical mometasone furoate for vulvar lichen sclerosus.

The Journal of reproductive medicine, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.